Identification of the underlying pattern for ruxolitinib failure in patients with myelofibrosis is a significant factor in determining appropriate treatment.
Although most notably associated with erythrocytosis, hematologic manifestations of polycythemia vera may also include leukocytosis and thrombocytosis.
Researchers sought to determine whether second cancers associated with MPNs affect a patient’s prognosis, and whether cytoreductive or antiplatelet therapies affect outcomes.
Researchers examined pregnancy outcomes in 102 patients with essential thrombocythemia.
One finding from this study was that VTE was more likely to occur at atypical sites in patients with myelofibrosis compared to those without the disease.